Cogent Biosciences, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 58.35 million compared to USD 38.59 million a year ago. Basic loss per share from continuing operations was USD 0.62 compared to USD 0.55 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.01 USD | +9.88% | -2.55% | +36.22% |
May. 23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
May. 23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.22% | 766M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024